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ABSTRACT
Introduction Less than 40% of patients with ovarian 
cancer (OC) in the USA receive stage- appropriate 
guideline- adherent surgery and chemotherapy. Black 
patients with cancer report greater depression, pain and 
fatigue than white patients. Lack of access to healthcare 
likely contributes to low treatment rates and racial 
differences in outcomes. The Ovarian Cancer Epidemiology, 
Healthcare Access and Disparities study aims to 
characterise healthcare access (HCA) across five specific 
dimensions—Availability, Affordability, Accessibility, 
Accommodation and Acceptability—among black, Hispanic 
and white patients with OC, evaluate the impact of HCA 
on quality of treatment, supportive care and survival, and 
explore biological mechanisms that may contribute to OC 
disparities.
Methods and analysis We will use the Surveillance 
Epidemiology and Ends Results dataset linked with 
Medicare claims data from 9744 patients with OC ages 65 
years and older. We will recruit 1641 patients with OC (413 
black, 299 Hispanic and 929 white) from cancer registries 
in nine US states. We will examine HCA dimensions in 
relation to three main outcomes: (1) receipt of quality, 
guideline adherent initial treatment and supportive care, 
(2) quality of life based on patient- reported outcomes and 
(3) survival. We will obtain saliva and vaginal microbiome 
samples to examine prognostic biomarkers. We will use 
hierarchical regression models to estimate the impact of 
HCA dimensions across patient, neighbourhood, provider 
and hospital levels, with random effects to account for 
clustering. Multilevel structural equation models will 
estimate the total, direct and indirect effects of race on 
treatment mediated through HCA dimensions.
Ethics and dissemination Result dissemination will 
occur through presentations at national meetings and in 
collaboration with collaborators, community partners and 
colleagues across othercancer centres. We will disclose 
findings to key stakeholders, including scientists, providers 
and community members. This study has been approved 
by the Duke Institutional Review Board (Pro00101872). 
Safety considerations include protection of patient privacy. 
All disseminated data will be deidentified and summarised.
BACKGROUND
In 2020, there were an estimated 21 750 newly 
diagnosed cases and an estimated 13 940 
deaths attributed to ovarian cancer (OC) in 
the USA,1 accounting for 1.2% of all cancers 
among women and 2.3% of all cancer deaths. 
Diagnosis at early stages, when the cancer is 
most amenable to treatment, is difficult due 
to the lack of easily recognisable symptoms 
and effective screening tests. Consequently, 
Strengths and limitations of this study
 ► Diverse sample population (black, white and 
Hispanic patients from nine different state cancer 
registries).
 ► Evaluation of multiple facets of healthcare ac-
cess (Accessibility, Acceptability, Affordability, 
Accommodation and Availability) in a population- 
based sample across multiple levels of influence 
with regard to multiple outcomes across the cancer 
care continuum.
 ► Incorporation of a cell to society approach by 
characterisation of measures across multiple lev-
els—biological (saliva and microbiome), patient (so-
ciodemographics, comorbidities, patient- reported 
outcomes) and social (dimensions of healthcare 
access).
 ► Potential for recall bias.
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up to 75% of patients with OC present with cancer that has 
spread regionally or has metastasised. For these patients, 
survival is highly dependent on the quality of treatment. 
However, data from the National Cancer Institute (NCI) 
Patterns of Care studies indicate that fewer than half of all 
patients with OC received guideline- recommended stage- 
appropriate surgery and multiagent chemotherapy treat-
ment.2 Lack of quality treatment also contributes to the 
low 5- year survival rate for OC, which is currently 47%. In 
addition, striking racial disparities in OC survival persist. 
Among white women, survival improved from 35% to 
47% between 1975–1977 and 2008–2014, but declined 
from 42% to 39% among black women in the same time 
period.3 Lack of access to advanced treatment options has 
been well documented as a major contributor to lower 
survival rates and marked disparities in OC survival,4 5 
however, few studies to our knowledge has comprehen-
sively evaluated racial differences across multiple dimen-
sions of healthcare access (HCA) to identify those most 
impactful for treatment and survival.
HCA is defined as five separate but inter- related dimen-
sions: Availability—the type, quality and quantity of 
healthcare resources; Affordability—the ability to pay 
for healthcare; Accessibility—the location of healthcare 
resources in relation to the patient; Accommodation—
the organisation of healthcare resources in relation to the 
patient’s constraints and preferences; and Acceptability—
the patient’s attitude, perceptions and quality of inter-
action with healthcare providers.6 7 Prior studies have 
examined some aspects of HCA dimensions in relation 
to OC outcomes, such as insurance status and hospital 
volume8 9; for instance, while black patients with breast 
cancer were more likely to reside in counties with greater 
availability of healthcare resources (e.g., greater number 
of oncology hospitals), compared with white patients,10 
they were less likely to receive surgery and experienced 
lower survival rates. This suggests that availability alone 
is insufficient for access to care and other dimensions 
must also be considered. Two HCA dimensions in partic-
ular, accommodation and acceptability, are not routinely 
captured in administrative claims databases and are 
particularly understudied, although these may be key 
to understanding how aspects of HCA, such as patient 
preferences, trust and communication with providers, 
which interact with other dimensions of HCA, and may 
be differential by race and impact OC outcomes.
In addition to examining HCA as a social determi-
nant of health, it is also important to evaluate biological 
mechanisms underlying OC prognosis and disparities. 
While several aetiological risk factors for OC have been 
established (including BRCA mutation, parity and oral 
contraceptive use),11 12 few studies have characterised 
biological and genomic factors predicting racial differ-
ences in OC prognosis . For instance, there is scientific 
evidence suggesting an important role for the cervicovag-
inal microbiome in OC risk and prognosis,12 and a recent 
study observed that black and Hispanic women were 
over- represented among patients that lacked significant 
lactobacilli and had a higher proportion of anaerobic 
bacteria.13 Racial differences in microbiome composi-
tion, and those associated with genetic ancestry, may be 
linked with OC prognosis and partly explain racial dispar-
ities observed in OC outcomes14 15 and deserve further 
scrutiny.
Therefore, the goal of the Ovarian Cancer Epidemi-
ology, Healthcare Access and Disparities (ORCHiD) 
study is to address these knowledge gaps by (1) fully char-
acterising HCA dimensions among black, Hispanic and 
white patients with OC, (2) evaluating the association 
of HCA dimensions with racial disparities in receipt of 
quality, guideline- adherent initial treatment, supportive 
care and survival, (3) and characterising the biological 
mechanisms underlying OC disparities. The conceptual 
framework for ORCHiD is presented in figure 1. This 
comprehensive approach is a necessary first step towards 
identifying specific interventions focused on important, 
modifiable social and biological factors to eliminate 
disparities.
METHODS AND ANALYSIS
Study design and organisation
The ORCHiD study design incorporates two distinct 
approaches: (1) a retrospective cohort design of black, 
Figure 1 Conceptual overview of ORCHiD aims. ORCHiD, Ovarian Cancer Epidemiology, Healthcare Access and Disparities; 
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Hispanic and white patients with OC ages 65–75 years 
(using secondary data from the Surveillance Epidemi-
ology and Ends Results (SEER)- Medicare linked dataset) 
and (2) a population- based prospective cohort design 
with primary survey data of black, Hispanic and white 
patients with OC ages 20–75 years identified from cancer 
registries in California, Georgia, Kentucky, New York, 
North Carolina, Texas, Maryland, Florida and Mississippi. 
In the SEER- Medicare cohort, we will evaluate the associ-
ation of three HCA dimensions measurable with admin-
istrative data (Affordability, Availability and Accessibility) 
in relation to guideline adherent initial treatment and 
supportive care and survival. In the prospective cohort, we 
will evaluate all five HCA dimensions using a combination 
of administrative claims data and self- reported measures 
in relation to guideline adherent treatment and survival, 
as well as patient- reported outcomes (PROs) such as pain, 
fatigue and depression.
Retrospective cohort study design
We obtained SEER- Medicare data on 9744 black, Hispanic 
and white patients with OC, stages I–IV, ages 65 years or 
older, diagnosed with a first primary OC between 2008 
and 2015. Patients were excluded if their OC was diag-
nosed at autopsy or death, or if OC was not either their 
first or second primary cancer diagnosis. Patients were 
required to have at least 12 months of continuous enrol-
ment in Medicare fee- for- service parts A and B prior to 
the SEER diagnosis, and to have at least one Medicare 
inpatient, outpatient or carrier claim with a diagnosis 
code for OC (International Classification of Disease ICD- 
9- CM and ICD- 10- CM diagnosis codes 183.0 or C569) 
within 2 months of the SEER diagnosis; the date of the 
earliest claim will serve as the patient’s exact OC diag-
nosis date as SEER provides only the month and year 
of diagnosis. Patients were required to have continuous 
fee- for- service Medicare enrolment in the 12 months 
following their diagnosis date, or until death. The SEER 
dataset is routinely linked with Medicare claims data for 
patients with cancer ages 65+, and includes all SEER data 
items (sociodemographics, cancer stage, subtype, date of 
initial diagnosis, vital status and survival time), Medicare 
claims data from the Center for Medicare and Medicaid 
Services (CMS)16 and linked external datasets. The SEER- 
Medicare cohort is linked with external data from the 
US Census Bureau American Community Survey (ACS), 
the Area Healthcare Resource file and the NCI hospital 
files to obtain data at the patient, neighbourhood, physi-
cian and hospital levels. The ACS census tract and ZIP 
code file was used to link region- specific socioeconomic 
data to the claims records; the Hospital file was used 
to determine whether a treatment facility was affiliated 
with an NCI designated cancer centre, whether a facility 
was ever non- accredited, total number of beds, number 
of Medicare/Medicaid certified beds, participation in 
Medicare/Medicaid, urban vs rural location, or teaching 
status as a measure of academic standing. SEER- Medicare 
provides the Hospital file linked to their identifiers. We 
then evaluated the three HCA dimensions—Availability, 
Affordability and Accommodation—that can be feasibly 
measured in SEER- Medicare.
Prospective cohort study design
We will recruit 1641 black, Hispanic and white patients 
with OC ages 20–75 years from nine population- based 
cancer registries including California, Georgia, Kentucky, 
New York, North Carolina, Texas, Maryland, Florida and 
Mississippi (figure 2). These registries cover a diverse 
range of patients, including typically difficult- to- reach 
populations, such as Appalachian whites in Kentucky and 
rural blacks in the Mississippi Delta. We chose to focus on 
this age group in the prospective cohort (20–75 years) 
because the median age at diagnosis for OC is 63 years, 
and 55% of cases are younger than 65 years at diagnosis, 
enabling us to examine OC outcomes among patients 
not captured in SEER- Medicare. Sociodemographic and 
clinical data from registry records will be used to identify 
patients eligible for the study based on: black, Hispanic or 
white race; between the ages of 20 and 75 at initial diag-
nosis; a resident of the registry geographical region at the 
time of diagnosis and initial contact; at least 6 months 
postdiagnosis; first primary clinically confirmed OC. 
To ensure that we have an adequate number of racially 
diverse participants, we will include patients diagnosed 
with any stage and subtype of OC and adjust for these vari-
ables in statistical models. We will also attempt to recruit 
all black patients with OC in each registry and use a strat-
ified random sampling approach to select white patients 
age matched to black patients on ages 20–64 and 65–75 
years. We will attempt to recruit all Hispanic patients in 
two registries—Texas and California—that have high 
Hispanic populations.
Prospective cohort recruitment
For each of the target state registries, registry staff will 
review patient data/records to confirm study eligibility. 
For eligible patients, a letter describing the study will 
be sent to the treating physician (when required by the 
registry). The letter will ask the physician to contact 
the registry if there are reasons the subject should not 
be contacted. If no reasons are reported or there is no 
response from the physician within 2–3 weeks, the regis-
tries will send eligible participants a letter informing 
them of their eligibility for the research study along with 
a preaddressed postage paid response card which may be 
used to select whether or not they want their names to be 
released to the ORCHiD study team. In some registries, 
if a response card is not received within 2 weeks, phone 
calls will be made by registry staff in an attempt to get 
verbal permission and only those who agree to have their 
names released will be forwarded to the ORCHiD study 
team for recruitment. At regular intervals, the ORCHiD 
research team will receive a list of eligible participants 
from participating registries. ORCHiD study staff will 
mail out a study packet containing an introduction letter, 
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the study consent form and a prepaid envelope. Between 
2 and 3 weeks after the study packet is mailed out, the 
study interviewers will begin making phone calls to partic-
ipants to enrol them into the study, answer any questions, 
conduct informed consent and complete the survey. 
Phone contact will follow a schedule of attempts during 
day, evening, and weekend hours. The ORCHiD study 
was granted a waiver of documentation of consent, there-
fore, verbal consent obtained during the phone call and 
documented by the interviewer on an institutional review 
board (IRB)- approved phone script enables the survey 
interview to occur during the same phone call. In addi-
tion, while not required, participants will be encouraged 
to also provide documentation of consent via an electronic 
consent form on REDCap or by signing and returning the 
mailed paper consent form. The study survey is expected 
to last 55–65 minutes and can be completed at one time 
during the call or rescheduled, if needed. On comple-
tion of the survey, the biospecimen substudy component 
will be introduced to participants and interested partic-
ipants will be administered a biospecimen consent and 
then subsequently mailed the biospecimen collection 
kit. An incentive of a US$25 gift card will be provided for 
completing the study survey, and an additional US$20 gift 
card for returning the biospecimen kit.
Study measures and data collection
To create the unique richness and depth of data for 
ORCHiD, we will use a variety of data sources as described 
below to characterise measures at the patient, neighbour-
hood, physician and hospital levels.
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Measuring HCA dimensions
The Penchansky and Thomas framework6 7 provides five 
dimensions of HCA. As OC outcomes are particularly 
impacted by access to care, we will use this framework as 
a comprehensive measure of access using variables rele-
vant to OC that can be measured at either the patient, 
neighbourhood, provider or health system levels using 
data sources as outlined in table 1. As part of forma-
tive work for ORCHiD, we conducted a comprehensive 
review of the literature to identify existing instruments 
to characterise HCA across all five dimensions. However, 
we noted significant challenges: (1) none of the existing 
instruments comprehensively assessed all five dimensions; 
most surveys covered aspects of one specific dimension 
for example, financial toxicity as part of the Affordability 
component, patient–provider communication as part of 
the Acceptability component, but these were not compre-
hensive even within each dimension; (2) none of the 
existing instruments appeared to have considered the 
varying experiences of different racial groups in devel-
oping the items, making it unclear if the questions would 
capture the experiences of black and Hispanic patients, 
the major focus of ORCHiD and (3) combining questions 
or subscales from various surveys into one HCA instrument 
Table 1 Healthcare access dimensions, component measures and geographic level of assessment
Dimension Measure Level of assessment Data source
Affordability
Price, willingness and ability 
to pay for healthcare services
Income Individual Survey*
Insurance type Individual Survey
Insurance co- pay Individual Survey
Out- of- pocket cost Individual Survey
Census tract Median Household 
income, poverty
Neighbourhood (census tract) US census
% Uninsured Neighbourhood (census tract) US census
Availability
Type, quality and volume of 
healthcare services in relation 
to patient need
Usual healthcare provider Individual Survey
No of hospitals Neighbourhood (county) Area resource file
No of Gyn- oncologists, Ob- Gyn Neighbourhood (county) Area resource file
Physician specialty Physician SEER- medicare
Physician ovarian cancer patient 
volume
Physician SEER- medicare
Hospital teaching status Hospital Area Resource File
Hospital quality metrics Hospital SEER- medicare
Accessibility
Location of healthcare 
services in relation to patients
Travel time (minutes) Individual Survey
Mode of transport Individual Survey
Distance to hospital (miles) Geographic Survey+Geographic 
Information System 
(GIS)
Rural/urban location Patient, hospital Survey+area resource 
file
Accommodation
Organisation of healthcare 
services and resources in 
relation to patients’ ability to 
accommodate such services
Hospital bed size Hospital Area resource file
Hospital average wait times Hospital Hospital information
Access to support services Individual Survey
Acceptability
Patient attitude to personal 
and practice characteristics of 
healthcare provider
Trust (oncologist, primary care 
provider)
Individual Survey
Comfort (oncologist) Individual Survey
Race concordance (oncologist) Individual, physician Survey
Reputation/credentials (oncologist) Individual Survey
Transportation/distance to facility Individual Survey
Time away from work/family Individual Survey
*Participant surveys conducted 6–12 months postdiagnosis for primary ovarian cancer diagnosis to establish healthcare access 
characteristics around the time of diagnosis that may influence choice of healthcare facility and provider.
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would likely result in limited validity with poor psycho-
metric properties. Therefore, we addressed these critical 
limitations by conducting an initial qualitative study that 
included focus group discussions and cognitive interviews 
with cancer survivors to provide content validation data 
for the HCA survey to be used in our prospective cohort. 
Additionally, the original framework was developed in the 
context of primary care. Data gained from focus groups 
identified how each HCA dimension applied to a socio-
economic and racially diverse group of patients with 
cancer, allowing us to obtain measures of access specific 
to cancer care in each of the dimensions. The process of 
concept elicitation with focus groups, cognitive interviews 
and pilot testing is described below and summarised in 
figure 3.
1. Draft survey: We began drafting a questionnaire by 
pulling survey items from existing, validated surveys 
that addressed the topics of interest. Validated ques-
tionnaires are instruments that have undergone eval-
uation to ensure the instrument measures what it is 
intended to measure.
2. Concept elicitation: To guide the development of sur-
vey questions that were not captured by existing instru-
ments, we conducted focus group discussions with 32 
female cancer survivors (63% black and 18% Hispan-
ic) using a semistructured interview guide. The focus 
groups solicited input regarding their perceptions of 
each dimension of HCA, experiences accessing care af-
ter their cancer diagnosis, and facilitators and barriers 
to receiving quality treatment. Information from the 
focus groups were synthesised and analysed and used 
to guide survey development. Focus group participants 
were provided a US$25 gift card for participation.
3. Cognitive testing: We conducted cognitive testing of 
the HCA survey items with in- depth interviews among 
seven patients with OC diagnosed at Duke University 
(three black, one Hispanic and three white patients). 
Interview participants were asked to answer the ques-
tionnaire, think about their responses (i.e., retrospec-
tive probing) and describe their thought processes 
after responding. The interviewer probed on (1) com-
prehension (level of understanding), (2) clarity (level 
of straightforward meaning), (3) knowledge and mem-
ory (ease of recall of information needed to respond) 
and (4) judgement (ease of fitting personal experienc-
es to the measure response options). Debriefing forms 
were completed for each interview and used by the 
study team to review findings and modify questions as 
needed. Participants were provided a US$25 gift card 
for participation.
4. Pilot testing: With the ORCHiD survey at near final 
version, having been edited for length, clarity and 
content, we conducted a pilot study of 50 patients with 
OC recruited from the Duke Cancer Center and the 
University of Alabama at Birmingham Comprehensive 
Cancer Center. The full- length survey was administered 
by phone (preferred option) or self- administered elec-
tronically. A small proportion of patients preferred to 
complete the paper version and were mailed a short-
ened version of the full survey to enhance completion. 
The biospecimen substudy component was also tested 
in this phase. Feedback from pilot study participants 
regarding the survey was incorporated into the draft 
version before being finalised for the main study. 
Participants were provided a US$25 gift card incentive 
for completing the survey and an additional US$20 gift 
card for providing biospecimen.
Measuring guideline-recommended treatment
In both the retrospective and prospective cohorts, we 
will use previously well- validated treatment algorithms 
combining registry and claims data to assess receipt of 
guideline- adherent OC treatments.17–19 We will compare 
treatments received to the treatments recommended 
in professional guidelines published by the National 
Comprehensive Cancer Network.20 We will also select 
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well- defined supportive care quality measures from the 
CMS Quality Payment Programme, including medications 
for treatment of pain, depression or anxiety. We will eval-
uate care quality for comorbid conditions, measured by 
hospitalisations and emergency room visits for potentially 
avoidable admissions related to suboptimal management 
of multimorbidity. Concordance between recommended 
treatment and treatment outcomes in this cohort will 
be assessed from multiple overlapping data sources: (1) 
patient- reported treatment information from the survey 
(in prospective cohort); there is evidence that patients 
can reliably report receipt of recent radiation and chemo-
therapy, although not the specific agents used,21–24 (2) 
cancer registry data on surgery and chemotherapy for all 
participants; these data have been shown to have a level 
of reliability similar to claims data,25 (3) claims data on 
treatment through linkages with Medicare or Medicaid 
claims data and (4) a manual review of medical records 
for patients in the Kentucky registry as further valida-
tion. These multiple layers of treatment information in 
the primary survey cohort will minimise the likelihood of 
misclassification and also enable us to assess the validity of 
treatment information obtained from survey data.
Measuring PROs and other patient variables
We will measure patient- reported symptoms using the 
Patient- Reported Outcomes Measurement Information 
System (PROMIS) four- item short forms in the prospec-
tive cohort study. PROMIS item banks have been exten-
sively tested,26 27 and short forms are reliable and valid for 
use in the general US population, in cancer- specific popu-
lations28 and in non- white and low- income subgroups.29–32 
We will assess four symptom domains widely recognised 
as prevalent and manageable in cancer survivors: fatigue, 
depression, anxiety and sleep disturbance. Self- efficacy 
for healthcare will also be assessed with a PROMIS 
measure.33 34 We will use two out of five possible subdo-
mains from this item bank: confidence in managing symp-
toms and confidence in managing medications and also 
assess functional status. Registry- derived data including 
sociodemographics, month and year of diagnosis, cancer 
site, histologic type, stage at diagnosis, survival time and 
vital status, and first course of therapy will be obtained for 
all patients in both cohorts. Since comorbidity status is a 
significant predictor of poor survival with marked racial 
differences, we will assess comorbidities in both cohorts. 
In the retrospective SEER- Medicare cohort, we use claims 
data to create a comorbidity index,35 and in the prospec-
tive cohort, we ask respondents about common and 
serious comorbid conditions adapted from the Charlson 
index. We also include measures of select risk factors 
(e.g., smoking, body mass index) that are both associated 
with poor survival and also potentially modifiable targets 
for improving outcomes.36 37
Biospecimen collection
Following completion of the survey in the prospective 
cohort, participants will be asked if they are interested 
in participating in future research. If they decline, no 
further studies will be introduced, however, if they agree, 
the participants will be offered the opportunity to partici-
pate in the biospecimen substudy. Interested participants 
will be asked to provide self- collected cervicovaginal 
microbiome specimen using the DNA Genotek OMR- 130 
kit (or similar) and saliva sample using DNA Genotek 
OGR- 500 kit (or similar). Samples will be shipped back to 
the study team at Duke for processing and analysis, and 
molecular data will be linked to clinical data obtained in 
the ORCHiD study for future analysis.
Patient and public involvement
Essentially, the goal of ORCHiD is to address these knowl-
edge gaps by (1) fully characterising HCA dimensions 
among black, Hispanic, and white patients with OC, 
(2) evaluating the association of HCA dimensions with 
racial disparities in receipt of quality, guideline- adherent 
initial treatment, supportive care and survival and (3) 
and characterising the biological mechanisms underlying 
OC disparities. Patients, cancer survivors and community 
members were involved in the study design, and contrib-
uted important insights into the recruitment and conduct 
of this research study. The study protocol was presented to 
the Duke Cancer Institute Community Advisory Council 
for feedback, and information obtained during the focus 
group with cancer survivors and the pilot study of ovarian 
cancer survivors were incorporated into the study design. 
Feedback on each step of the study design, pilot and 
ongoing recruitment activities are disseminated back to 
patients and survivors, with a plan to provide ongoing 
updates.
Analytical plan
Descriptive statistics will be conducted for all variables 
in each study cohort overall and by race, region and age 
group. We will compare categorical variables by group 
using χ2 tests, and continuous variables using t- tests 
or non- parametric tests as appropriate. Hierarchical 
multiple regression analysis will be used to evaluate the 
association between each main exposures of interest 
(HCA dimensions) and study outcomes (guideline- 
adherent treatment, PROs, survival), accounting for 
the clustering of patients within neighbourhoods (e.g., 
county), physicians and hospitals, and adjusting for a wide 
range of relevant study covariates. Variable collinearity 
will be assessed using the variance inflation factor (VIF) 
method. Covariates with VIF values of 10 or higher will be 
dropped from the multivariable models. Additionally, the 
planned factor analysis will be used to create composite 
scores for the HCA dimensions; these scores will be used 
in lieu of adjustment for each individual variable, which 
should help to reduce issues of collinearity between vari-
ables of interest. Non- response from the survey and its 
characteristics will be recorded and evaluated to identify 
potential biases. We will conduct multiple imputation, 
for instance, full conditional specification approach, to 
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missing at random, non- standard conditionally specified 
models will be used.
Sample size and power analysis
To estimate the sample size for the primary survey cohort, 
we focused our power calculation on the outcome for Aim 
2: receipt of guideline- adherent treatment. A 10%–14% 
difference in the receipt of guideline- adherent treatment 
was observed between black and white patients ages 65+ 
in a population- based cohort,2 38 with larger differences 
observed in those less than age 65.4 39 We will recruit all 
potential black patients with OC from participating regis-
tries, age group- matched white patients and all potential 
Hispanic patients with OC from Texas and California 
registries. We will, therefore, have a total sample size of 
9744 patients in the SEER- Medicare cohort, and 1641 
patients (413 blacks, 299 Hispanics and 929 whites) in the 
primary survey cohort. Accounting for intraclass correla-
tion coefficient (conservatively assumed to not exceed 
0.1) within the multilevel statistical model, and assuming 
60% of study subjects reside in neighbourhoods with 
high HCA availability, we will have 80% power to detect 
racial differences in treatment as small as 6% using SEER- 
Medicare data and as small as 14% using the primary 
survey cohort data. Based on similar assumptions, we will 
be well powered to detect hazard ratios as small as 1.09 in 
SEER- Medicare data, and as small as 1.21 in the primary 
survey cohort. We will also have 80% power to detect 
at least a 1.5- point difference (or 0.15*SD) in PROMIS 
scores.
DISCUSSION
The ORCHiD study will generate novel and valuable data 
on a diverse patient population to identify salient factors 
associated with disparities in initial treatment, supportive 
care and quality of life among patients with OC. This 
study incorporates a cell to society approach by character-
ising measures across multiple levels—biological (saliva 
and microbiome), patient (sociodemographics, comor-
bidities, PROs) and social (HCA dimensions)—in rela-
tion to OC outcomes and racial disparities, making our 
study uniquely comprehensive in scope and addressing 
several major limitations in the current literature. HCA 
is fundamental to receipt of quality, guideline- adherent 
treatment, which is critical to survival. Understanding 
racial differences in salient HCA dimensions that incor-
porate the experiences of black and Hispanic patients will 
provide unique insights.
Measures of HCA are derived from the Penchansky 
and Thomas framework that was published in 1981. This 
comprehensive study provided a framework for dimen-
sions of HCA and specified five in particular (Availability, 
Affordability, Accommodation, Acceptability and Accessi-
bility). 40 Data collected will allow us to identify specific 
interventions to address barriers to HCA among cancer 
patients in order to ensure that all patients receive quality 
and timely treatment.
The first scientific papers for ORCHiD will describe 
results of the qualitative analysis of HCA focus groups 
with diverse cancer survivors and present empirical data 
on racial differences in affordability, availability and 
accessibility HCA dimensions on quality of initial treat-
ment from the retrospective SEER- Medicare cohort 
study. Subsequent papers will describe HCA in relation to 
supportive care and quality of life, and report on all five 
HCA dimensions from the prospective cohort.
The study design for ORCHiD is motivated primarily 
by an urgent need to close the treatment and survival 
gap between black and white patients with OC—most, if 
not all of the benefits of improved treatment strategies 
over the past several decades have been experienced 
by white patients, while survival rates have declined 
for black women. Importantly, when black and white 
women who received complete guideline- adherent treat-
ment are compared, racial disparities are no longer 
apparent.41 42 There is a unique opportunity to address 
this gap by understanding the drivers of poor access to 
care among black and Hispanic women and developing 
targeted interventions to address them. As with most 
observational studies that rely on self- report, there are 
several inherent limitations to our study design, such 
as the potential for recall bias, inability to make causal 
inferences and potential for differential misclassification 
of exposures. However, our study design addresses these 
challenges by: (1) collecting data from several distinct 
sources, including standardised cancer registry data and 
external secondary data, (2) applying advanced statistical 
methodological approaches to account for the multilevel 
clustered nature of the dataset and to mitigate selection 
bias, (3) conducting extensive prestudy activities to ensure 
that our recruitment materials are compelling among 
black and Hispanic, hard- to- reach populations and (4) 
using existing validated survey measures on outcomes of 
interest, such as PROs.
By using high- quality data and a comprehensive cell 
to society approach, we will not only characterise racial 
disparities in OC care and survival, but we will also deter-
mine the role of differential access to care and biolog-
ical mechanisms that sustain these disparities, enabling 
us to assess the relative importance of each factor inde-
pendently and jointly. Our data will provide useful infor-
mation regarding which HCA dimensions and biological 
factors are most relevant and highlight specific areas 
where tailored clinical and public health strategies are 
needed to improve quality care for all patients with 
OC. While we are unable to infer causality, our data will 
provide relevant information as a guide to investigating 
specific healthcare policies, such as value- based payment 
models or collaborative care models, regarding strategies 
that may promote the quality and value of healthcare 
services while reducing disparities in health outcomes.
Ethics and dissemination
Duke University’s Institutional Review Board reviewed 
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(Pro00101872). As it involves collection of personal 
health information, we have a detailed security plan that 
involves deidentification of survey answers and biolog-
ical samples when possible. Sensitive information is 
kept on encrypted and firewalled databases. This study 
has considerable potential for contributing high- impact 
findings, many of which might have direct public health 
benefit. There are two parts to our plan: First, the study’s 
investigators are very active in national and international 
forums dealing with their respective areas of expertise. 
Through the leading roles they play at such gatherings, 
they will present the findings from this new study on a 
regular basis and discuss the public health implications as 
well as implications for future research. Second, cancer 
clinicians and scientists are among the key target audi-
ences for the proposed study. The study measurements 
represent the cutting edge of implementation science, 
oncology and cancer disparities research. We will continue 
to foster wide interest in these areas by keeping the prac-
titioners apprised of our findings and their relevance. We 
plan reach out to other cancer centres to describe our 
research findings, and to target national meetings such 
as AcademyHealth, American Assoication for Cancer 
Research, American Society for Preventive Oncology, 
American Society of Clinical Oncology, and Society for 
Epidemiologic Research, among others. We will dissem-
inate findings to key stakeholders, including, scientists 
and providers, and to community members through 
presentations of findings to the Community Advisory 
Board, at local, state and local conferences, and actively 
seek out opportunities to engage community members. 
We will also disseminate findings to our study participants 
via a newsletter at the end of the study.
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